Back to News
Market Impact: 0.3
Artelo Reports ART27.13 Matches Semaglutide Weight Loss In Obesity Model
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Artelo Biosciences reported new nonclinical data for ART27.13 showing weight loss comparable to semaglutide in an obesity model. The company also indicated greater weight loss under additional, unspecified conditions in the truncated report, providing early supportive evidence for its clinical-stage obesity therapy program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ARTL0.72
More News
- Japan’s corporate leaders sound alarm over weak yen — even dollar-earners are voicing concerns
- Fed hikes again - an AI-Picked insurer is still cashing in
- Berkshire May Boost Japan Trading House Holdings, Itochu Says
- Berkshire may boost holdings in Japan’s trading houses- Bloomberg
- The Competition's Response to Tesla Robotaxi Day
- Generac's stock soars more than 30% after Amazon deal cements its status as AI power player